-
FDA Approves Tecentriq Combination as Adjuvant Therapy for Specific Colon Cancer
A New Milestone in Colon Cancer Treatment Genentech has announced a significant development in oncology with the FDA approval of Tecentriq (atezolizumab) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy. This treatment is now indicated as an adjuvant therapy for patients with stage IIB or IIC colon cancer that has been completely resected. Understanding the Indication…
-
A New Frontier in Colon Cancer: First Patient Dosed in Phase III Cadonilimab Trial
Advancing Immunotherapy for Colon Cancer In a significant milestone for oncology research, Akeso, Inc. has officially announced that the first patient has been dosed in a global Phase III clinical trial evaluating cadonilimab. This study focuses on the perioperative treatment of patients with locally advanced colon cancer. Understanding Cadonilimab Cadonilimab is a novel, potentially first-in-class…